Cargando…
Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer
This study was performed to evaluate the efficacy and toxicity of low-dose paclitaxel/cisplatin chemotherapy in patients with metastatic or recurrent gastric cancer that had failed 5-fluorouracil/platinum-based chemotherapy. Thirty-two patients with documented progression on or within 6 months after...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694374/ https://www.ncbi.nlm.nih.gov/pubmed/17923737 http://dx.doi.org/10.3346/jkms.2007.22.S.S115 |
_version_ | 1782168081473208320 |
---|---|
author | Lee, Keun-Wook Kim, Jee Hyun Yun, Tak Song, Eun Kee Na, Im il Shin, Hyunchoon Oh, So Yeon Choi, In Sil Oh, Do-Youn Kim, Dong-Wan Im, Seock-Ah Kim, Tae-You Lee, Jong Seok Heo, Dae Seog Bang, Yung-Jue Kim, Noe Kyeong |
author_facet | Lee, Keun-Wook Kim, Jee Hyun Yun, Tak Song, Eun Kee Na, Im il Shin, Hyunchoon Oh, So Yeon Choi, In Sil Oh, Do-Youn Kim, Dong-Wan Im, Seock-Ah Kim, Tae-You Lee, Jong Seok Heo, Dae Seog Bang, Yung-Jue Kim, Noe Kyeong |
author_sort | Lee, Keun-Wook |
collection | PubMed |
description | This study was performed to evaluate the efficacy and toxicity of low-dose paclitaxel/cisplatin chemotherapy in patients with metastatic or recurrent gastric cancer that had failed 5-fluorouracil/platinum-based chemotherapy. Thirty-two patients with documented progression on or within 6 months after discontinuing 5-fluorouracil/platinum-based chemotherapy were enrolled. As a second-line treatment, paclitaxel (145 mg/m(2)) and cisplatin (60 mg/m(2)) was administered on day 1 every 3 weeks. Among 32 patients enrolled, 8 (25%) responded partially to paclitaxel/cisplatin, 8 (25%) had stable disease, and 14 (44%) had progressive disease. Two patients (6%) were not evaluable. The median time to progression (TTP) and overall survival for all patients were 2.9 months and 9.1 months, respectively. The most common hematologic toxicity was anemia (47%). Grade 3 neutropenia developed in three patients (9%), but no other grade 3/4 hematologic toxicity occurred. The most common non-hematologic toxicities were emesis (31%) and peripheral neuropathy (38%). Three cases (9%) of grade 3/4 emesis and 2 cases (6%) of grade 3 peripheral neuropathy developed. In conclusion, low-dose paclitaxel and cisplatin chemotherapy showed moderate activity with favorable toxicity profiles. However, relatively short TTP of this regimen warrants the development of more effective paclitaxel-based regimens other than combination with cisplatin in these patients as second-line therapies. |
format | Text |
id | pubmed-2694374 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | The Korean Academy of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-26943742009-06-11 Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer Lee, Keun-Wook Kim, Jee Hyun Yun, Tak Song, Eun Kee Na, Im il Shin, Hyunchoon Oh, So Yeon Choi, In Sil Oh, Do-Youn Kim, Dong-Wan Im, Seock-Ah Kim, Tae-You Lee, Jong Seok Heo, Dae Seog Bang, Yung-Jue Kim, Noe Kyeong J Korean Med Sci Original Article This study was performed to evaluate the efficacy and toxicity of low-dose paclitaxel/cisplatin chemotherapy in patients with metastatic or recurrent gastric cancer that had failed 5-fluorouracil/platinum-based chemotherapy. Thirty-two patients with documented progression on or within 6 months after discontinuing 5-fluorouracil/platinum-based chemotherapy were enrolled. As a second-line treatment, paclitaxel (145 mg/m(2)) and cisplatin (60 mg/m(2)) was administered on day 1 every 3 weeks. Among 32 patients enrolled, 8 (25%) responded partially to paclitaxel/cisplatin, 8 (25%) had stable disease, and 14 (44%) had progressive disease. Two patients (6%) were not evaluable. The median time to progression (TTP) and overall survival for all patients were 2.9 months and 9.1 months, respectively. The most common hematologic toxicity was anemia (47%). Grade 3 neutropenia developed in three patients (9%), but no other grade 3/4 hematologic toxicity occurred. The most common non-hematologic toxicities were emesis (31%) and peripheral neuropathy (38%). Three cases (9%) of grade 3/4 emesis and 2 cases (6%) of grade 3 peripheral neuropathy developed. In conclusion, low-dose paclitaxel and cisplatin chemotherapy showed moderate activity with favorable toxicity profiles. However, relatively short TTP of this regimen warrants the development of more effective paclitaxel-based regimens other than combination with cisplatin in these patients as second-line therapies. The Korean Academy of Medical Sciences 2007-09 2007-09-30 /pmc/articles/PMC2694374/ /pubmed/17923737 http://dx.doi.org/10.3346/jkms.2007.22.S.S115 Text en Copyright © 2007 The Korean Academy of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lee, Keun-Wook Kim, Jee Hyun Yun, Tak Song, Eun Kee Na, Im il Shin, Hyunchoon Oh, So Yeon Choi, In Sil Oh, Do-Youn Kim, Dong-Wan Im, Seock-Ah Kim, Tae-You Lee, Jong Seok Heo, Dae Seog Bang, Yung-Jue Kim, Noe Kyeong Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer |
title | Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer |
title_full | Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer |
title_fullStr | Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer |
title_full_unstemmed | Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer |
title_short | Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer |
title_sort | phase ii study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694374/ https://www.ncbi.nlm.nih.gov/pubmed/17923737 http://dx.doi.org/10.3346/jkms.2007.22.S.S115 |
work_keys_str_mv | AT leekeunwook phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT kimjeehyun phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT yuntak phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT songeunkee phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT naimil phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT shinhyunchoon phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT ohsoyeon phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT choiinsil phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT ohdoyoun phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT kimdongwan phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT imseockah phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT kimtaeyou phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT leejongseok phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT heodaeseog phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT bangyungjue phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer AT kimnoekyeong phaseiistudyoflowdosepaclitaxelandcisplatinasasecondlinetherapyafter5fluorouracilplatinumchemotherapyingastriccancer |